$OBIO
Orchestra Biomed Holdings Inc Stock $obio

$obio Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000121390023005085 Filed on January 25, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$1.164M	$0.00	$0.00
YoY Change
Cost Of Revenue	$44.00K	$53.00K	$211.0K
YoY Change	4.76%	-11.67%	6.03%
Gross Profit	$1.120M	$1.050M	$3.322M
YoY Change	-2766.67%	-141.83%	-438.63%
Gross Profit Margin	96.22%
Selling, General & Admin	$4.411M	$876.7K	$3.080M
YoY Change	875.99%	852.44%	680.29%
% of Gross Profit	393.84%	83.5%	92.72%
Research & Development	$8.254M	$7.543M	$21.95M
YoY Change	137.59%	113.68%	70.25%
% of Gross Profit	736.96%	718.38%	660.6%
Depreciation & Amortization	$71.00K	$70.00K	$222.0K
YoY Change	47.92%	40.0%	22.65%
% of Gross Profit	6.34%	6.67%	6.68%
Operating Expenses	$12.67M	$876.7K	$3.080M
YoY Change	2702.3%	852.44%	680.29%
Operating Profit	-$11.55M	$173.3K	-$3.080M
YoY Change	125.14%	-106.66%	680.3%
Interest Expense	$351.0K	$0.00	$345.1K
YoY Change	2359.71%	-100.0%	2057.13%
% of Operating Profit		0.0%
Other Income/Expense, Net			$120.0K
YoY Change			0.0%
Pretax Income	-$10.94M	-$876.7K	-$2.735M
YoY Change	2399.49%	896.16%	622.14%
Income Tax
% Of Pretax Income
Net Earnings	-$10.94M	-$876.7K	-$2.735M
YoY Change	2399.49%	896.16%	622.14%
Net Earnings / Revenue	-939.86%
Basic Earnings Per Share	-$0.40		-$0.17
Diluted Earnings Per Share	-$0.40	-$0.08	-$0.17
COMMON SHARES
Basic Shares Outstanding	11.21M shares	11.21M shares	16.43M shares
Diluted Shares Outstanding	27.64M shares		16.43M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$127.1M	$64.09M	$83.70M
YoY Change	8860.1%	3552.99%	4670.64%
Cash & Equivalents	$18.70M	$175.2K	$19.78M
Short-Term Investments	$108.4M	$63.92M	$63.92M
Other Short-Term Assets	$110.8M	$64.45M	$619.0K
YoY Change	155289.26%	137992.99%	1226.33%
Inventory	$232.0K	$276.0K	$276.0K
Prepaid Expenses		$123.9K
Receivables	$76.00K	$96.00K	$96.00K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$129.9M	$299.1K	$84.69M
YoY Change	8615.78%	-83.39%	4602.05%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.453M	$1.489M	$3.676M
YoY Change	-59.64%		228.21%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$2.495M	$2.495M	$2.495M
YoY Change	-98.44%	-98.44%	-98.44%
Other Assets	$421.0K	$4.711M	$4.711M
YoY Change	-57.9%		582.75%
Total Long-Term Assets	$6.401M	$67.78M	$10.88M
YoY Change	-96.0%	-57.65%	-93.2%
TOTAL ASSETS
Total Short-Term Assets	$129.9M	$299.1K	$84.69M
Total Long-Term Assets	$6.401M	$67.78M	$10.88M
Total Assets	$136.3M	$68.08M	$95.57M
YoY Change	-15.63%	-57.93%	-40.94%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.765M	$376.9K	$3.968M
YoY Change	2568.66%	27056.34%	285367.63%
Accrued Expenses	$3.256M	$1.367M	$6.073M
YoY Change	1504.49%	9558.86%	3599.66%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due		$0.00	$0.00
YoY Change			-100.0%
Total Short-Term Liabilities	$12.06M	$1.744M	$18.57M
YoY Change	3833.26%	953.38%	11115.42%
LONG-TERM LIABILITIES
Long-Term Debt	$9.527M	$9.490M	$9.490M
YoY Change
Other Long-Term Liabilities	$249.0K	$196.0K	$14.98M
YoY Change	-98.66%		-13.87%
Total Long-Term Liabilities	$249.0K	$196.0K	$24.47M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$12.06M	$1.744M	$18.57M
Total Long-Term Liabilities	$249.0K	$196.0K	$24.47M
Total Liabilities	$36.53M	$7.344M	$43.04M
YoY Change	518.43%	27.37%	646.47%
SHAREHOLDERS EQUITY
Retained Earnings	-$210.7M	-$6.945M
YoY Change		76.16%
Common Stock	$3.000K	$445.00
YoY Change		0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$99.75M	-$6.945M	$52.53M
YoY Change
Total Liabilities & Shareholders Equity	$136.3M	$68.08M	$95.57M
YoY Change	-15.63%	-57.93%	-40.94%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$10.94M	-$876.7K	-$2.735M
YoY Change	2399.49%	896.16%	622.14%
Depreciation, Depletion And Amortization	$71.00K	$70.00K	$222.0K
YoY Change	47.92%	40.0%	22.65%
Cash From Operating Activities	-$14.38M	-$560.1K	-$1.579M
YoY Change	4185.42%	1842.63%	479.86%
INVESTING ACTIVITIES
Capital Expenditures	$35.00K	$54.00K	$591.0K
YoY Change	-25.53%	-55.0%	115.69%
Acquisitions
YoY Change
Other Investing Activities	-$43.49M	$0.00	$92.59M
YoY Change
Cash From Investing Activities	-$43.53M	$0.00	$92.59M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net			$6.446M
YoY Change
Cash From Financing Activities	$56.82M	0.000	-$92.59M
YoY Change	129.45%
NET CHANGE
Cash From Operating Activities	-$14.38M	-560.1K	-$1.579M
Cash From Investing Activities	-$43.53M	0.000	$92.59M
Cash From Financing Activities	$56.82M	0.000	-$92.59M
Net Change In Cash	-$1.089M	-560.1K	-$1.579M
YoY Change	224.51%	1842.63%
FREE CASH FLOW
Cash From Operating Activities	-$14.38M	-$560.1K	-$1.579M
Capital Expenditures	$35.00K	$54.00K	$591.0K
Free Cash Flow	-$14.42M	-$614.1K	-$2.170M
YoY Change	3668.1%	312.59%	297.23%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital		usd
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	20450000	shares
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	E9
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	40 10th Avenue
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-39421
CY2022	dei	Entity Registrant Name EntityRegistrantName	HEALTH SCIENCES ACQUISITIONS CORPORATION 2
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Floor 7
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10014
CY2022	dei	City Area Code CityAreaCode	(646)
CY2022	dei	Local Phone Number LocalPhoneNumber	597-6980
CY2022	dei	Security12b Title Security12bTitle	Ordinary Shares, par value $0.0001 per share
CY2022	dei	Trading Symbol TradingSymbol	HSAQ
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	true
CY2022Q2	dei	Entity Public Float EntityPublicFloat	159400000	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	11212117	shares
CY2022	dei	Auditor Name AuditorName	WithumSmith+Brown, PC
CY2022	dei	Auditor Location AuditorLocation	New York
CY2022	dei	Auditor Firm AuditorFirmId	100
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	175161	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1754460	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	123918	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	46667	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	299079	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	1801127	usd
CY2022Q4	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	67776498	usd
CY2021Q4	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	160022447	usd
CY2022Q4	us-gaap	Assets Assets	68075577	usd
CY2021Q4	us-gaap	Assets Assets	161823574	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	376930	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1388	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1366825	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14151	usd
CY2021Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	150000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1743755	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	165539	usd
CY2022Q4	hsaq	Deferred Underwriting Commissions In Connection With The Initial Public Offering DeferredUnderwritingCommissionsInConnectionWithTheInitialPublicOffering	5600000	usd
CY2021Q4	hsaq	Deferred Underwriting Commissions In Connection With The Initial Public Offering DeferredUnderwritingCommissionsInConnectionWithTheInitialPublicOffering	5600000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	7343755	usd
CY2021Q4	us-gaap	Liabilities Liabilities	5765539	usd
CY2022Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	6762117	shares
CY2022Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	6762117	shares
CY2021Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	16000000	shares
CY2021Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	16000000	shares
CY2022Q4	us-gaap	Temporary Equity Redemption Price Per Share TemporaryEquityRedemptionPricePerShare	10.01
CY2021Q4	us-gaap	Temporary Equity Redemption Price Per Share TemporaryEquityRedemptionPricePerShare	10
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	67676498	usd
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	160000000	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4450000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4450000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4450000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4450000	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	445	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	445	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-6945121	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-3942410	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-6944676	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-3941965	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	68075577	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	161823574	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2960264	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	274756	usd
CY2022	us-gaap	Administrative Fees Expense AdministrativeFeesExpense	120000	usd
CY2021	us-gaap	Administrative Fees Expense AdministrativeFeesExpense	120000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-3080264	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-394756	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	345141	usd
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	16003	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2735123	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-378753	usd
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16425826	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20450000	shares
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-3563212	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-378753	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-3941965	usd
CY2022	us-gaap	Increase In Carrying Amount Of Redeemable Preferred Stock IncreaseInCarryingAmountOfRedeemablePreferredStock	267588	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2735123	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-6944676	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2735123	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-378753	usd
CY2022	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	345141	usd
CY2021	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	16003	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	77251	usd
CY2021	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-75811	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	375542	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-12422	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1352674	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-60995	usd
CY2022	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-150000	usd
CY2021	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	120000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1579299	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-272362	usd
CY2022	hsaq	Cash Withdrawn From Trust Account To Redeem Public Shares CashWithdrawnFromTrustAccountToRedeemPublicShares	92591090	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	92591090	usd
CY2022	hsaq	Redemption Of Public Share RedemptionOfPublicShare	92591090	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-92591090	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-1579299	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-272362	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1754460	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2026822	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	175161	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1754460	usd
CY2022	hsaq	Description Of Private Placement Warrant DescriptionOfPrivatePlacementWarrant	Simultaneously with the closing of the Initial Public Offering, the Company consummated the private placement (the “Private Placement”) with the Sponsor of (i) 450,000 ordinary shares (the “Private Placement Shares”), at a price of $10.00 per Private Placement Share (for a total purchase price of $4.5 million), and (ii) 1,500,000 warrants (the “Private Placement Warrants”) at a price of $1.00 per Private Placement Warrant (for a total purchase price of $1.5 million), generating gross proceeds to the Company of $6.0 million (see Note 4).
CY2022	hsaq	Percentage Held In Trust Account PercentageHeldInTrustAccount	0.80	pure
CY2022	hsaq	Public Per Share PublicPerShare	10
CY2022	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	5000001	usd
CY2022	hsaq	Ordinary Share Value Percentage OrdinaryShareValuePercentage	0.20	pure
CY2022	hsaq	Redeem Shares Percentage RedeemSharesPercentage	1	pure
CY2022Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	10
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	175000	usd
CY2022Q4	hsaq	Working Capital Deficit WorkingCapitalDeficit	1800000	usd
CY2022	us-gaap	Long Term Purchase Commitment Amount LongTermPurchaseCommitmentAmount	10000000	usd
CY2022Q4	us-gaap	Purchase Obligation PurchaseObligation	10000000	usd
CY2022	hsaq	Proposed Business Combination Description ProposedBusinessCombinationDescription	In addition, the Sponsor has agreed that 25% or 1,000,000 shares of its New Orchestra common stock received in the domestication will be forfeited to New Orchestra on the first business day following the fifth anniversary of the closing unless, as to 500,000 shares, the VWAP (as defined in the Merger Agreement) of the New Orchestra common stock is greater than or equal to $15.00 per share over any 20 Trading Days (as defined in the Merger Agreement) within any 30-Trading Day period, and as to the remaining 500,000 shares, the VWAP of the New Orchestra common stock is greater than or equal to $20.00 per share over any 20-Trading Days within any 30-Trading Day period. In addition, subject to the closing of the Orchestra Business Combination, the Sponsor has agreed to forfeit 50% of its Private Placement Warrants, comprising 750,000 Private Placement Warrants, for no consideration. Further, the Sponsor and the other Initial Shareholders prior to the Company’s initial public offering have agreed to subject the 4,000,000 shares of New Orchestra common stock to be received in the domestication in exchange for the 4,000,000 Insider Shares and 450,000 shares of New Orchestra common stock to be received in the domestication in exchange for the 450,000 Private Placement Shares, to a lock-up for up to 12 months.
CY2022	hsaq	Extension Redemptions And Private Purchase Description ExtensionRedemptionsAndPrivatePurchaseDescription	In connection with the vote to approve the Extension Proposal, the holders of 9,237,883 Public Shares properly exercised their right to redeem their shares for cash at a redemption price of approximately $10.02 per share, for an aggregate redemption amount of approximately $92.6 million. As such, approximately 57.7% of the Public Shares were redeemed and approximately 42.3% of the Public Shares remain outstanding. After the satisfaction of such redemptions, the balance in the Company’s Trust Account was $67.8 million.
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the consolidated financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2022	hsaq	Underwriting Agreement Description UnderwritingAgreementDescription	The Company granted the underwriters a 45-day option from the effective date of the registration statement relating to the Initial Public Offering to purchase up to 2,086,956 additional ordinary shares at the Initial Public Offering price less the underwriting discounts and commissions.
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Concentration of Credit Risk</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash accounts in a financial institution which, at times, may exceed the federal depository insurance coverage of $250,000, and investments held in Trust Account. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2022Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2022Q4	hsaq	Underwriting Discount Rate UnderwritingDiscountRate	0.2
CY2022Q4	hsaq	Shares Subject To Possible Redemption SharesSubjectToPossibleRedemption	6762117	shares
CY2021Q4	hsaq	Shares Subject To Possible Redemption SharesSubjectToPossibleRedemption	16000000	shares
CY2022	hsaq	Warrants To Purchase Ordinary Shares WarrantsToPurchaseOrdinaryShares	1500000	shares
CY2020Q3	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	160000000	usd
CY2020Q3	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	9400000	usd
CY2020Q3	hsaq	Defered Underwriting Commissions DeferedUnderwritingCommissions	5600000	usd
CY2022	hsaq	Underwriting Discount Fee Deferred UnderwritingDiscountFeeDeferred	0.35
CY2022Q4	us-gaap	Investment Owned Balance Principal Amount InvestmentOwnedBalancePrincipalAmount	6000000	usd
CY2022	us-gaap	Related Party Transaction Description Of Transaction RelatedPartyTransactionDescriptionOfTransaction	The Initial Shareholders agreed not to transfer, assign or sell any of their Insider Shares (except to certain permitted transferees) until, with respect to 50% of the Insider Shares, the earlier of six months after the date of the consummation of the initial Business Combination and the date on which the closing price of the Company’s ordinary shares equals or exceeds $12.50 per ordinary share for any 20 trading days within a 30-trading day period following the consummation of the initial Business Combination, and, with respect to the remaining 50% of the Insider Shares, six months after the date of the consummation of the initial Business Combination, or earlier in each case if, subsequent to the initial Business Combination, the Company completes a liquidation, merger, stock exchange or other similar transaction which results in all of the shareholders having the right to exchange their ordinary shares for cash, securities or other property.
CY2020Q2	us-gaap	Payments Of Loan Costs PaymentsOfLoanCosts	300000	usd
CY2020Q3	hsaq	Borrowed Amount BorrowedAmount	300000	usd
CY2022	us-gaap	Debt Conversion Description DebtConversionDescription	The notes would either be paid upon consummation of the initial Business Combination, without interest, or, at the lender’s discretion, up to $500,000 of such loans may be converted upon consummation of the Business Combination into additional private warrants at a price of $1.00 per warrant.
CY2022	us-gaap	Other Expenses OtherExpenses	120000	usd
CY2021	us-gaap	Other Expenses OtherExpenses	120000	usd
CY2022	hsaq	Accrued Expenses Related Party Outstanding AccruedExpensesRelatedPartyOutstanding	0	usd
CY2021	hsaq	Accrued Expenses Related Party Outstanding AccruedExpensesRelatedPartyOutstanding	150000	usd
CY2020Q3	hsaq	Aggregate Purchase To Ordinary Shares AggregatePurchaseToOrdinaryShares	2500000	shares
CY2020Q3	us-gaap	Accelerated Share Repurchases Initial Price Paid Per Share AcceleratedShareRepurchasesInitialPricePaidPerShare	10
CY2020Q3	hsaq	Aggregate Purchase Price AggregatePurchasePrice	25000000	usd
CY2020Q3	us-gaap	Investment Income Investment Expense InvestmentIncomeInvestmentExpense	15000000	usd
CY2022	us-gaap	Origination Of Loan To Purchase Common Stock OriginationOfLoanToPurchaseCommonStock	10000000	usd
CY2022	us-gaap	Payments Of Ordinary Dividends PaymentsOfOrdinaryDividends	20000000	usd
CY2022Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	10
CY2022	hsaq	Business Combination Amount BusinessCombinationAmount	60000000	usd
CY2022	hsaq	Purchase Agreement Amount PurchaseAgreementAmount	10000000	usd
CY2022Q3	us-gaap	Federal Funds Purchased FederalFundsPurchased	1000000	usd
CY2022Q3	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	10.01
CY2022	hsaq	Shareholder Support Agreement And Forfeiture Description ShareholderSupportAgreementAndForfeitureDescription	In addition, the Sponsor has agreed that 25% or 1,000,000 shares of its New Orchestra common stock received in the domestication will be forfeited to New Orchestra on the first business day following the fifth anniversary of the closing of the Orchestra Business Combination unless, as to 500,000 shares, the VWAP (as defined in the Merger Agreement) of the New Orchestra common stock is greater than or equal to $15.00 per share over any 20 Trading Days (as defined in the Merger Agreement) within any 30-Trading Day period, and as to the remaining 500,000 shares, the VWAP of the New Orchestra common stock is greater than or equal to $20.00 per share over any 20-Trading Days within any 30-Trading Day period. Further, subject to the closing of the Orchestra Business Combination, the Sponsor has agreed to forfeit 50% of its warrants, comprising 750,000 warrants for no consideration.
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022	us-gaap	Common Stock Voting Rights CommonStockVotingRights	Holders of the Company’s ordinary shares are entitled to one vote for each share.
CY2022Q4	us-gaap	Excess Stock Shares Outstanding ExcessStockSharesOutstanding	11212117	shares
CY2021Q4	us-gaap	Excess Stock Shares Outstanding ExcessStockSharesOutstanding	20450000	shares
CY2022Q4	hsaq	Shares Subject To Possible Redemption SharesSubjectToPossibleRedemption	6762117	shares
CY2021Q4	hsaq	Shares Subject To Possible Redemption SharesSubjectToPossibleRedemption	16000000	shares
CY2021	hsaq	Gross Proceeds Received From Initial Public Offerings GrossProceedsReceivedFromInitialPublicOfferings	160000000	usd
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	9418420	usd
CY2021	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	9418420	usd
CY2021	hsaq	Ordinary Share Subject To Possible Redemption OrdinaryShareSubjectToPossibleRedemption	160000000	usd
CY2022	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	-92591090	usd
CY2022	hsaq	Increase In Redemption Value Of Ordinary Shares Subject To Possible Redemption IncreaseInRedemptionValueOfOrdinarySharesSubjectToPossibleRedemption	267588	usd
CY2022	hsaq	Ordinary Share Subject To Possible Redemption OrdinaryShareSubjectToPossibleRedemption	67676498	usd
CY2022	us-gaap	Stock Issued During Period Shares Purchase Of Assets StockIssuedDuringPeriodSharesPurchaseOfAssets	1	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	11.5
CY2022Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2021Q4	us-gaap	Assets Held In Trust AssetsHeldInTrust	160022447	usd
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	00-0000000
CY2022Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital		usd
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.17
CY2021	hsaq	Cash Withdrawn From Trust Account To Redeem Public Shares CashWithdrawnFromTrustAccountToRedeemPublicShares		usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2021	hsaq	Redemption Of Public Share RedemptionOfPublicShare		usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001814114

Files In Submission

Name	View Source	Status
0001213900-23-005085-index-headers.html	Edgar Link	pending
0001213900-23-005085-index.html	Edgar Link	pending
0001213900-23-005085.txt	Edgar Link	pending
0001213900-23-005085-xbrl.zip	Edgar Link	pending
f10k2022ex21_healthscien2.htm	Edgar Link	pending
f10k2022ex31-1_healthscien2.htm	Edgar Link	pending
f10k2022ex31-2_healthscien2.htm	Edgar Link	pending
f10k2022ex32_healthscien2.htm	Edgar Link	pending
f10k2022ex4-4_healthscien2.htm	Edgar Link	pending
f10k2022_healthsciences2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
hsaq-20221231.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
hsaq-20221231_cal.xml	Edgar Link	unprocessable
hsaq-20221231_def.xml	Edgar Link	unprocessable
hsaq-20221231_pre.xml	Edgar Link	unprocessable
hsaq-20221231_lab.xml	Edgar Link	unprocessable
f10k2022_healthsciences2_htm.xml	Edgar Link	completed
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$OBIO
Orchestra Biomed Holdings Inc Stock $obio

2023 Q1 Form 10-K Financial Statement

#000121390023005085 Filed on January 25, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OBIO Orchestra Biomed Holdings Inc Stock $obio

2023 Q1 Form 10-K Financial Statement

#000121390023005085 Filed on January 25, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OBIO
Orchestra Biomed Holdings Inc Stock $obio